Sonoma Pharmaceuticals Inc. (SNOA): A Technical Analysis

SNOA has 36-month beta value of 1.29. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for SNOA is 15.38M, and currently, short sellers hold a 0.77% ratio of that float. The average trading volume of SNOA on April 04, 2024 was 1.99M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

SNOA) stock’s latest price update

Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA)’s stock price has gone rise by 8.97 in comparison to its previous close of 0.14, Accesswire reported 2024-03-28 that BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced that it will be presenting at two upcoming investor conferences in Denver and New York. Trickle Research Spring 2024 Microcap Conference Sonoma will be presenting at the Trickle Research Spring 2024 Microcap Conference at Ball Arena in Denver, Colorado on April 2nd, 2024.

SNOA’s Market Performance

Sonoma Pharmaceuticals Inc. (SNOA) has seen a 0.00% fall in stock performance for the week, with a 5.33% gain in the past month and a -13.19% plunge in the past quarter. The volatility ratio for the week is 15.10%, and the volatility levels for the past 30 days are at 12.24% for SNOA. The simple moving average for the past 20 days is 7.44% for SNOA’s stock, with a -69.74% simple moving average for the past 200 days.

SNOA Trading at 2.38% from the 50-Day Moving Average

After a stumble in the market that brought SNOA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.61% of loss for the given period.

Volatility was left at 12.24%, however, over the last 30 days, the volatility rate increased by 15.10%, as shares surge +0.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.60% lower at present.

During the last 5 trading sessions, SNOA remain unchanged, which changed the moving average for the period of 200-days by -87.94% in comparison to the 20-day moving average, which settled at $0.1471. In addition, Sonoma Pharmaceuticals Inc. saw -12.42% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for SNOA

Current profitability levels for the company are sitting at:

  • -0.36 for the present operating margin
  • 0.37 for the gross margin

The net margin for Sonoma Pharmaceuticals Inc. stands at -0.41. The total capital return value is set at -0.38. Equity return is now at value -82.87, with -35.56 for asset returns.

Based on Sonoma Pharmaceuticals Inc. (SNOA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -12.96. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -15.2.

Currently, EBITDA for the company is -4.45 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 0.04. The receivables turnover for the company is 4.28for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.98.

Conclusion

To put it simply, Sonoma Pharmaceuticals Inc. (SNOA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts